Management of Non-Metastatic TNBC with gBRCA1/2 Mutations

Introduction to Treatment Guidelines

The National Comprehensive Cancer Network recommends that capecitabine and olaparib should not be given concurrently in patients with non-metastatic triple-negative breast cancer and germline BRCA1/2 mutations, due to insufficient safety data and no established clinical benefit 1, 2, 3

For patients with residual disease after neoadjuvant chemotherapy, the National Comprehensive Cancer Network guidelines suggest choosing one agent, not both concurrently: if germline BRCA1/2 mutation is present, olaparib 300 mg orally twice daily for 1 year is the preferred option (Category 1 recommendation) 1, 2
If no germline BRCA1/2 mutation, capecitabine is indicated for TNBC with residual disease after taxane-, alkylator-, and anthracycline-based preoperative chemotherapy 1, 2, 4

The OlympiA trial demonstrated significant improvement in invasive disease-free survival at 3 years with olaparib: 85.9% vs 77.1% (HR 0.58; 99.5% CI, 0.41-0.82; P<0.001) 5
The CREATE-X trial showed improved DFS (HR 0.70; 95% CI 0.53-0.92; P=0.01) and OS (HR 0.59; 95% CI 0.39-0.90; P=0.01) with capecitabine in TNBC patients with residual disease 4

Overlapping hematologic toxicity is a concern with concurrent use of capecitabine and olaparib, including anemia, neutropenia, and thrombocytopenia 1, 4
Olaparib is associated with grade 3/4 anemia, neutropenia, and thrombocytopenia, while capecitabine is associated with hand-foot syndrome, diarrhea, and myelosuppression 1, 4

For patients with gBRCA1/2-mutated TNBC and residual disease, prioritize olaparib as it has Category 1 evidence specifically for this population 1, 2
Start olaparib after completion of all local treatments, including radiation therapy, and continue for 1 year 1, 2, 5
Monitor complete blood counts regularly for hematologic toxicity 5